MBOT - Microbot Medical Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.703
-0.017 (-2.36%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.720
Open0.721
Bid0.600 x 1400
Ask0.660 x 3000
Day's Range0.701 - 0.732
52 Week Range0.580 - 1.550
Volume74,318
Avg. Volume326,485
Market Cap23.819M
Beta-0.08
PE Ratio (TTM)N/A
EPS (TTM)-0.229
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.75
Trade prices are not sourced from all markets
  • GlobeNewswire22 days ago

    Microbot Medical Strengthens Global IP with Issued Patent in India Covering the Company’s ViRob™ Technology Platform

    Microbot™, which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body.

  • GlobeNewswire29 days ago

    Microbot Medical Inc. Announces European Patent Office's Intent to Grant Patent for Device for the Prevention of Shunt Stenosis

    Microbot Medical Inc. (Nasdaq CM:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that the European Patent Office (EPO) has notified the Company that it will grant a patent for Application No. 12837337.0, covering a device for the prevention of stenosis in blood vessels, especially for use on blood vessels adjacent to a hemodialysis shunt. Microbot™, which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016.

  • GlobeNewswire2 months ago

    Microbot Medical Inc. Schedules its Periodical Townhall Meeting for Monday, June 4th at 9:00 a.m., Eastern Time

    Microbot Medical Inc. (MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it will host its periodical Townhall Meeting on Monday, June 4, 2018 at 9:00 a.m., Eastern Time.  Harel Gadot, CEO, President and Chairman, Hezi Himelfarb, General Manager and Chief Operating Officer and Simon Sharon, Chief Technology Officer, will review the recent milestone achievements, primarily development and pre-clinical results as well as share the path forward for the Company, and will be available to address participant questions. In-vitro study, which was performed at Wayne State University, supports the SCS’s potential as a viable technology for preventing occlusion in shunts used to treat hydrocephalus.

  • GlobeNewswire2 months ago

    Microbot Medical Announces Successful Completion of Pre-Clinical Study Performed at Washington University in St. Louis

    “In this study we tested the material and structure properties of Microbot’s SCS™ catheters surgically implanted into juvenile pigs with hydrocephalus,” said Dr. McAllister.  “The safety profile of the Microbot SCS™ was compared to results from a pig that received a standard (commercial) catheter commonly used for the clinical treatment of hydrocephalus as well as from pigs that received no treatments for hydrocephalus.

  • GlobeNewswire2 months ago

    Microbot Medical Closes Acquisition of Novel Technology from CardioSert Ltd.

    Microbot Medical Inc. (NASDAQ CM:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced the closing of the previously-announced acquisition of a novel patent-protected technology from CardioSert Ltd.  Following the closing, the Company owns CardioSert’s innovative technology, including R&D information, technical know-how and intellectual property. CardioSert was part of a technological incubator supported by the Israel Innovation Authorities (formerly known as the Office of the Chief Scientist, or OCS), and its device has successfully completed pre-clinical testing.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Tiffany & Co. (NYSE: TIF ) stock was trading higher ...

  • GlobeNewswire2 months ago

    Microbot Medical Announces Receiving a Notification of Granting a Patent Right for its ViRob™ Technology Platform in China

    Microbot Medical Inc. (Nasdaq CM:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that the State Intellectual Property Office of China has issued a Notification of Granting a Patent Right for Chinese Patent Application No. 201410432156.7, which covers the Company’s ViRob™ technology platform. The application covers an autonomous vibration-driven device for motion through a lumen.

  • ACCESSWIRE2 months ago

    Wired News - Microbot Medical Shares Results from the In-Vitro Study of its Self-Cleaning Shunt

    LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Microbot Medical Inc. (NASDAQ: MBOT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MBOT as the Company's latest news hit the wire. On May 21, 2018, the medical device Company, which is specializing in the design and development of transformational micro-robotic medical technologies, declared the results of its pre-clinical study evaluating the Company's Self-Cleaning Shunt (SCS). Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Microbot Medical.

  • GlobeNewswire2 months ago

    Microbot Medical Successfully Completes Pre-Clinical Study for its Self-Cleaning Shunt

    Microbot Medical Inc. (NASDAQ CM:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today provided the results of a pre-clinical study assessing the Company’s Self-Cleaning Shunt (SCS). “Initial results from the first phase of the study, conducted in an in-vitro 3D cell culture system built to mimic the ventricular environment, showed that cells attach, grow and spread across the shunt drainage holes of the Microbot SCS,” said Dr. Harris, Assistant Professor of Chemical Engineering and Materials Science, Wayne State University.

  • Is Microbot Medical Inc’s (NASDAQ:MBOT) CEO Salary Justified?
    Simply Wall St.2 months ago

    Is Microbot Medical Inc’s (NASDAQ:MBOT) CEO Salary Justified?

    Harel Gadot is the CEO of Microbot Medical Inc (NASDAQ:MBOT), which has recently grown to a market capitalization of US$37.62M. Recognizing whether CEO incentives are aligned with shareholders is aRead More...

  • GlobeNewswire2 months ago

    Microbot Medical Announces Receiving Notice of Allowance for a U.S. Patent covering its Self-Cleaning Shunt (SCS)™ Device

    Microbot Medical Inc. (MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Patent Application No. 15/187,003, covering the Company’s Self-Cleaning Shunt (SCS)™ device. “We are making the necessary moves as we prepare for the next development phase of our Self-Cleaning Shunt, such as the recent move to our new R&D facilities and the expected studies’ results by the end of this quarter,” commented Harel Gadot, CEO, President and Chairman.  “Protecting our innovation remains a core principle to strengthening the device and Microbot’s positioning and since we became a publicly-traded company we have continued to establish and expand our IP portfolio globally.

  • GlobeNewswire2 months ago

    Microbot Medical Moves to State-of-the-Art Facility to Meet Next Phase of the Company’s Development Efforts

    Microbot Medical Inc. (NASDAQ CM:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, relocated its global Research & Development facility to the Caesarea Business and Industrial Park, located in Caesarea, Israel.  The Company’s global headquarters are located in Hingham, MA. “With the anticipated data we expect to receive by the end of the current quarter from the two ongoing studies for our lead SCS product, and the pending closing of the acquisition of the innovative technology from CardioSert, we have established the necessary infrastructures to scale up our development and manufacturing activities,” commented Harel Gadot, Chief Executive Officer, President and Chairman.

  • Is Microbot Medical Inc’s (MBOT) CEO Pay Justified?
    Simply Wall St.7 months ago

    Is Microbot Medical Inc’s (MBOT) CEO Pay Justified?

    Harel Gadot took the helm as Microbot Medical Inc’s (NASDAQ:MBOT) CEO and grew market cap to USD$48.45M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...

  • ACCESSWIRE10 months ago

    Today's Research Reports on Stocks to Watch: Synthetic Biologics and Microbot Medical

    NEW YORK, NY / ACCESSWIRE / September 18, 2017 / Shares of both Synthetic Biologics and Microbot Medical soared this past Friday after the companies had exciting news to share with investors. Synthetic ...